Merck KGaA

2021-01-20 — INTR@PID lung trial (bintrafusp alfa) halted

Event: Independent monitors recommended stopping the INTR@PID Lung 037 trial for futility; Merck KGaA and GSK's comparator study was unlikely to meet endpoints — the stock fell as much as ~7% intraday (later around -3.1%). [4]

Narrative: Investor perception shifted to caution on Merck's late-stage oncology ambitions; the pharmaceuticals pipeline was viewed as higher-binary risk while Life-Science and Electronics businesses were seen as the steadier growth drivers. [4]

Technical: Immediate drawdown / short-term downtrend and elevated volatility on the news. [4]

2021-02-05 — Expanded BioNTech partnership (lipid supply for mRNA vaccines)

Event: Merck KGaA agreed to accelerate and increase lipid supplies to BioNTech/Pfizer for the BNT162b2 vaccine, boosting deliveries toward end-2021. [2]

Narrative: Reinforced the company's role as a critical Life-Science supplier in the pandemic recovery; investors increasingly valued recurring demand for lab supplies and reagents. [2], [8]

Technical: Supportive to the stock's recovery and part of the broader 2021 uptrend driven by Life-Science demand. [2], [8]

2021-05-04 — FY2021 guidance raised after strong Q1

Event: After a strong Q1 (net sales €4.63bn), Merck raised full-year 2021 guidance for net sales (~€18.5–19.5bn), EBITDA pre (~€5.4–5.8bn) and EPS pre (~€7.50–8.20). [3]

Narrative: Market narrative shifted toward an accelerating growth story; investors bought the thesis that the "Big 3" businesses would sustain above-trend performance. [3], [8]

Technical: Continued uptrend / rally as guidance upgrades were priced in. [3]

2021 Q2 — Strong operational beat and upgraded outlook

Event: Q2 results showed Group net sales +18.2% to €4.9bn, EBITDA pre +46.7% to €1.6bn, EPS pre +72.3% to €2.24; the Group again updated and raised FY2021 guidance (sales €18.8–19.7bn; EBITDA pre €5.6–6.0bn). [8]

Narrative: Reinforced perception of Merck as a multi-axis growth company (Life Science, Healthcare launches, Semiconductor Solutions); investors framed the name as a compounder rather than a cyclical chemicals play. [8]

Technical: Strong rally / sustained uptrend through mid-2021 as results beat expectations. [8]

2021-09-30 — Mutual termination of bintrafusp alfa agreement with GSK

Event: Merck and GSK mutually ended their bintrafusp alfa collaboration; no milestone payments were made and no future obligations remained under the agreement. [9]

Narrative: Reduced a headline clinical binary risk; investors incrementally refocused valuation on organic Life-Science and Electronics growth rather than pipeline upside from that program. [9], [8]

Technical: Short consolidation / range as market repriced clinical risk and refocused on other growth drivers. [9]

2021-09-20 — Major Electronics investment announced

Event: Merck announced plans to invest >€3bn (≈$3.5bn) through 2025 into its Electronics business to expand capacity, R&D and consider bolt-on M&A amid the chip/ display cycle. [10]

Narrative: Signalled intentional diversification and exposure to secular demand in semiconductors and displays; investors saw a higher-capex, cyclical growth leg complementing Life-Science. [10]

Technical: Positive catalyst that helped sustain the 2021 uptrend; intermittent volatility around capex guidance but structurally supportive. [10]

2022-03-03 — Fiscal 2021 final results published (record year)

Event: Fiscal 2021 full-year results: Group sales +12.3% to €19.7bn; EBITDA pre +17.3% to €6.1bn; EPS pre €8.72; management proposed a dividend increase to €1.85. [1]

Narrative: Execution across the "Big 3" validated management's multi-pillar growth thesis; investors rewarded delivery with a re-rating toward higher multiples for recurring Life-Science revenue. [1], [8]

Technical: Post-results confirmation of the uptrend; momentum into 2022 remained constructive. [1]

2022 Q3 through FY2022

Event: Q3 2022: Group net sales +16.8% to €5.8bn, EBITDA pre +16.7% to €1.8bn; the Group narrowed FY2022 ranges. FY2022 (reported early-Mar 2023): Group net sales +12.9% to €22.2bn; EBITDA pre +12.2% to €6.8bn; dividend proposed €2.20. [13], [12]

Narrative: Investors treated Merck as resilient — organic growth held up even as raw material, energy and logistics costs rose and currencies proved volatile; emphasis shifted to margin management and medium-term guidance. [13], [12]

Technical: Choppy consolidation / range with an overall upward bias as markets weighed growth versus margin/FX pressures. [13], [12]

2023-07-01 — CFO appointment and continued Life-Science capacity build

Event: Helene von Roeder became CFO effective 1 July 2023 (succeeding Marcus Kuhnert); the Group continued capacity and R&D investments (e.g., Allentown distribution campus expansion, biosafety test facilities in the UK, increased Nantong reagent capacity). [32]

Narrative: Management transition was orderly; the company doubled down on Life-Science infrastructure, reinforcing the narrative that Life-Science is the durable earnings engine. [32]

Technical: Neutral-to-positive — stock remained in a medium-term uptrend with periodic consolidations around execution news. [32]

2024 — M&A and portfolio reshaping toward Life-Science

Event: Merck closed several Life-Science bolt-ons: Mirus Bio (closed 31 Jul 2024; purchase price US$617m), acquired Unity-SC (31 Oct 2024) and Hub Organoids (23 Dec 2024); the Group also announced the divestment of the Surface Solutions unit (announced 25 Jul 2024). [26]

Narrative: Clear strategic reallocation of capital from cyclical Electronics subsegments toward higher-margin, recurring Life-Science services and tools; investors increasingly viewed M&A as execution of that pivot. [26]

Technical: Episodic breakouts on deal announcements; overall positive re-rating as the market priced a more focused Life-Science profile. [26]

2025-04-28 — Agreed acquisition of SpringWorks Therapeutics (~$3.9bn)

Event: Merck KGaA announced a cash offer to acquire SpringWorks to strengthen its oncology / rare-disease portfolio (≈$3.9bn equity valuation); the deal depended on approvals and shareholder consent. [31]

Narrative: A deliberate push to rebuild the pharma pipeline via targeted bolt-ons after prior late-stage program disappointments; investors reacted with short-term volatility but acknowledged strategic logic to offset patent and pipeline risks. [31]

Technical: Volatile trading / brief rebound after the announcement; market digested acquisition premium versus pipeline upside. [31]

2026-03-05 — U.S. policy / regulatory wins and commitments

Event: Merck reached an agreement with the U.S. administration to expand access to its IVF therapies in the U.S., filed Pergoveris for expedited review under the FDA Commissioner's National Priority Voucher program, and agreed with the U.S. Department of Commerce on relief from Section-232 pharmaceutical tariffs while committing further U.S. investment. [25]

Narrative: Reduced regulatory and trade-policy risk in the U.S. and improved commercial runway for fertility products; investors saw these as tangible, near-term demand and margin support. [25]

Technical: Supportive catalyst that helped a short-term rally and underpinned a bullish bias into mid-2026. [25]

2026-06-25 — Agreed purchase of Bio-Techne (~$11.3bn)

Event: Merck KGaA agreed to acquire Bio-Techne for about $11.3bn — its largest deal in over a decade — to expand its life-science research and bioprocessing footprint; management raised 2026 adjusted-operating-profit guidance citing stronger lab-supply demand. [6]

Narrative: Market framed the deal as a decisive scale-up of the Life-Science tools business to create a larger recurring-revenue franchise; investors balanced integration and price risk against potential structural growth and higher margins. [6]

Technical: Immediate volatility on deal size and integration risk; overall viewed as a strategic breakout toward a higher-growth profile, supporting bullish medium-term momentum. [6]

2026-07-11 — Market snapshot (latest price)

Event: Share price 139.7.

Narrative: Market pricing in mid-2026 reflects the mix of aggressive M&A and capex to build Life-Science scale, recent U.S. policy/regulatory wins, and remaining operational/integration risks.

Technical: Trading in an elevated consolidation band with bullish bias following consecutive strategic M&A catalysts.